Proof-of-concept study shows non-invasive brain stimulation efficient as treatment for ADHD in children
August 2, 2023Research and Development ADHD, Hebrew University of Jerusalem, Psychiatry, brain stimulation, clinical trial, university of surrey
Researchers from the University of Surrey, UK, and the Hebrew University of Jerusalem, Israel, have found that non-invasive brain stimulation …
MyMD reports statistically significant results from phase 2 trial for sarcopenia/age-related frailty
August 2, 2023Research and Development Musculo-skeletal disorder, MyMD, clinical trial, sarcopenia
MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 …
The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19
August 1, 2023Research and Development COVID-19, Infections and infestations, NIH, clinical trials, long covid
As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials of its ‘Researching COVID to …
Merck shares data from phase 3 trial for breast cancer treatment
August 1, 2023Research and Development MSD, Merck, Oncology, breast cancer, keytruda
Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …
GSK’s Jemperli approved for treatment of endometrial cancer
August 1, 2023Research and Development FDA, GSK, Jemperli, Oncology, dostarlimab, endometrial cancer
GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …
Research shows neonatal stem cells could be used as treatment for Crohn’s disease
July 31, 2023Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal
Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …
FDA approves a second OTC naloxone nasal spray
July 31, 2023Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
Biogen to acquire Reata Pharmaceuticals
July 31, 2023Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …
Eli Lilly shares data from two phase 3 tirzepatide studies
July 28, 2023Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss
Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …
AstraZeneca’s Alexion partners with Pfizer for rare disease therapies
July 28, 2023Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease
Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …
Hummingbird Bioscience initiates phase 1b trials for sqNSCLC
July 27, 2023Research and Development Hummingbird Bioscience, Omico, Oncology, clinical trials, sqNSCLC
Hummingbird Bioscience has announced the initiation of two phase 1b clinical trials taking place in Australia. The trials will evaluate …
American Heart Association awards $2.1m to research link between migraine, strokes and CVD
July 27, 2023Research and Development American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
July 26, 2023Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …
Biovian announces investment in manufacturing facility in Finland
July 26, 2023Manufacturing and Production Biovian, Pharmacy, facility, manufacturing
Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of over €50m to expand its …
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial
July 25, 2023Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial
Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …
ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention
July 24, 2023Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
July 24, 2023Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Aevice Health gains FDA clearance for respiratory monitoring platform
July 21, 2023Research and Development Aevice Health, Devices, FDA, respiratory monitoring
Remote respiratory monitoring solutions company Aevice Health has announced that it has received clearance from the US Food and Drug …
BioIVT acquires PrecisionMed for neurology and oncology research
July 21, 2023Sales and Marketing Neurology, Oncology, neurology, oncology
BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …
Latest content
FibroFind appoints Lee Borthwick as CEO
